Skip to main content

Table 6 Response rate of each of the five symptoms before and after Treatment

From: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

SymptomsIFNα1b
Group
Control
Group
WP
Coughing0.61 ± 0.400.52 ± 0.403706.50.156
Expectoration0.70 ± 0.440.53 ± 0.493897.50.024
Chest pain0.16 ± 0.370.20 ± 0.4031820.535
Pulmonary rales0.49 ± 0.490.34 ± 0.463799.50.042
Respiratory rate0.43 ± 0.500.32 ± 0.473677.50.141